Next 10 |
home / stock / apls / apls articles
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.2% on Friday. Shares of NIKE, Inc. (NYSE:NKE) fell sharply in...
WALTHAM, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will host a fire...
Apellis received $375 million in funding at close, with ability to access an additional $100 million Majority of initial proceeds used to buy out...
WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that 14 abstracts, 11 of which are ...
WALTHAM, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will host a con...
Apellis Pharmaceuticals (NASDAQ:APLS) has outperformed the market over the past 5 years by 11.97% on an annualized basis producing an average annua...
WALTHAM, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will host a fir...
Apellis Pharmaceuticals (NASDAQ:APLS) has outperformed the market over the past 5 years by 10.69% on an annualized basis producing an average annua...
SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP, investigates potential violations of federal and...
News, Short Squeeze, Breakout and More Instantly...
Apellis Pharmaceuticals Inc. Company Name:
APLS Stock Symbol:
NASDAQ Market:
Apellis Pharmaceuticals Inc. Website:
WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the marketing authorization application (MAA) of i...
2024-06-19 19:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SYFOVRE is the only approved GA treatment to demonstrate a visual function benefit in a prespecified endpoint Data presented at the Clinical Trials at the Summit Meeting WALTHAM, Mass., June 10, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announ...